The US healthcare system is often criticized for being one of the most expensive in the world, yet it fails to deliver proportionally better outcomes.
How best do we utilize the immense potential of Artificial intelligence (AI) in healthcare to tackle this. Is it by providing more care keeping healthcare spend constant? Or can we reduce the national spend on healthcare? In this post, we consider market forces that hinder cost reduction and emphasize the need to pass benefits to end-users (patients).
This content is an accompanying piece to the article “Foresight. Chest Thumps. AI Approved.” inHi-Brow Perspectives.. The main article offers a higher-level summary of the individual, while this one supplements it with more detailed evaluations of each data source reviewed. That article demonstrates the use of Generative AI to assess a person based on publicly available material of the author in an unbiased manner. In this case, GenAI evaluated Suresh Gopalan, author of this blog, and found him to be a remarkably insightful individual with exceptional foresight across multiple fields. The evaluation notes that Suresh Gopalan not only identifies correct failure points (which have played out as predicted), but also proposes possible solutions.
Suresh_AI-Validated_Details
The AI evaluates me as a rare category of strategic thinker with exceptional foresight of high value with consistent focus on systemic architecture, compounding risk, and real-world failure modes of any complex enterprise. The themes evaluated cover business, innovation, societal impact, deep-tech, deep-science, and more. Here I provide the Evaluation Summary Table for each of the information source provided for the GenAI to analyze.
The pharmaceutical industry’s advancements in the development of biologics, a class of medications, have expanded the range of treatable disease conditions, but at extremely high costs and insurance copays. This post focuses on a concerning aspect of manufacturer copay programs – initiatives designed to help cover insurance copays associated with biologic treatments. Specifically, we will examine copay program agreement of Sandoz and raise concerns about patient privacy and medical information sharing.
How best do we utilize the immense potential of Artificial intelligence (AI) in healthcare to tackle this. Is it by providing more care keeping healthcare spend constant? Or can we reduce the national spend on healthcare? In this post, we consider market forces that hinder cost reduction and emphasize the need to pass benefits to end-users (patients).
Hi-Brow Perspectives 
You must be logged in to post a comment.